Adial Pharmaceuticals Shares Rise 78% After Positive Trial Data for AD04

Dow Jones04-10

By Chris Wack

Adial Pharmaceuticals shares were up 78% at $2.01 after the company provided promising clinical results, strong safety profile and high compliance among patients administered AD04, or low-dose ondansetron.

The stock hit its 52-week low of 77 cents on Feb. 23, and is down 73% in the past 12 months.

AD04 is the company's lead investigational new drug product, being developed for the treatment of alcohol use disorder.

The biopharmaceutical company said the study provided a comprehensive analysis of the liver safety profile of AD04 compared to a placebo in individuals with AUD and a specific 5-marker genetic profile.

According to the study, low-dose AD04 didn't significantly change biochemical markers of liver injury. No significant adverse effects were observed due to oral low-dose AD04 treatment.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

April 10, 2024 10:30 ET (14:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426418426?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-10 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2426418426","market":"sg","top_or_hot":-1,"title":"Adial Pharmaceuticals Shares Rise 78% After Positive Trial Data for AD04","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n   <a href=\"https://laohu8.com/S/ADIL\">Adial Pharmaceuticals</a> shares were up 78% at $2.01 after the company provided promising clinical results, strong safety profile and high compliance among patients administered AD04, or low-dose ondansetron. \n</p>\n<p>\n  The stock hit its 52-week low of 77 cents on Feb. 23, and is down 73% in the past 12 months. \n</p>\n<p>\n  AD04 is the company's lead investigational new drug product, being developed for the treatment of alcohol use disorder. \n</p>\n<p>\n  The biopharmaceutical company said the study provided a comprehensive analysis of the liver safety profile of AD04 compared to a placebo in individuals with AUD and a specific 5-marker genetic profile. \n</p>\n<p>\n  According to the study, low-dose AD04 didn't significantly change biochemical markers of liver injury. No significant adverse effects were observed due to oral low-dose AD04 treatment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2024 10:30 ET (14:30 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adial Pharmaceuticals Shares Rise 78% After Positive Trial Data for AD04</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdial Pharmaceuticals Shares Rise 78% After Positive Trial Data for AD04\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-10 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\nAdial Pharmaceuticals shares were up 78% at $2.01 after the company provided promising clinical results, strong safety profile and high compliance among patients administered AD04...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADIL","symbol_name":"Adial Pharmaceuticals","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2426418426","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426418426","pubTimestamp":1712759400,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Adial Pharmaceuticals shares were up 78% at $2.01 after the company provided promising clinical results, strong safety profile and high compliance among patients administered AD04, or low-dose ondansetron.The stock hit its 52-week low of 77 cents on Feb. 23, and is down 73% in the past 12 months.AD04 is the company's lead investigational new drug product, being developed for the treatment of alcohol use disorder.The biopharmaceutical company said the study provided a comprehensive analysis of the liver safety profile of AD04 compared to a placebo in individuals with AUD and a specific 5-marker genetic profile.According to the study, low-dose AD04 didn't significantly change biochemical markers of liver injury. No significant adverse effects were observed due to oral low-dose AD04 treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADIL":"Adial Pharmaceuticals","BK4007":"制药"},"translate_title":"Adial Pharmaceuticals股价上涨78%，AD04试验数据为阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADIL":1},"content_text":"By Chris Wack \n\n\n \n\n\nAdial Pharmaceuticals shares were up 78% at $2.01 after the company provided promising clinical results, strong safety profile and high compliance among patients administered AD04, or low-dose ondansetron. \n\n\n  The stock hit its 52-week low of 77 cents on Feb. 23, and is down 73% in the past 12 months. \n\n\n  AD04 is the company's lead investigational new drug product, being developed for the treatment of alcohol use disorder. \n\n\n  The biopharmaceutical company said the study provided a comprehensive analysis of the liver safety profile of AD04 compared to a placebo in individuals with AUD and a specific 5-marker genetic profile. \n\n\n  According to the study, low-dose AD04 didn't significantly change biochemical markers of liver injury. No significant adverse effects were observed due to oral low-dose AD04 treatment. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2024 10:30 ET (14:30 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426418426"}